CHAARTED: ADT Plus Docetaxel in Prostate Cancer

Video

Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.

Michael J. Morris, MD, member of the medical oncology and genitourinary oncology services at Memorial Sloan Kettering Cancer Center, was a discussant on the ECOG-led phase III randomized CHAARTED trial that studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.

Dr. Morris talks about side effects seen during the trial, what accounted for the increase in the time to development of castration resistance seen, as well as what he thinks the effect will be if results of the FIRSTANA trial show cabazitaxel to be superior to docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

Recent Videos
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Related Content